NAVLE Primates

Marburg Virus Disease in Primates – NAVLE Study Guide

📅 March 28, 2026 ⏱ 25 min read

Marburg virus disease (MVD) is a highly fatal viral hemorrhagic fever affecting humans and nonhuman primates.

Overview and Clinical Importance

Marburg virus disease (MVD) is a highly fatal viral hemorrhagic fever affecting humans and nonhuman primates. Caused by Marburg virus (MARV) and Ravn virus (RAVV), both members of the family Filoviridae, this disease is a significant zoonotic threat with case fatality rates ranging from 24% to 90%. Marburg virus was first identified in 1967 during simultaneous outbreaks in Marburg and Frankfurt, Germany, and Belgrade, Yugoslavia, following exposure to infected African green monkeys imported from Uganda for polio vaccine production.

For veterinarians, understanding MVD is critical for biosafety when working with imported primates, recognizing clinical presentations in zoological collections, and preventing zoonotic transmission. This disease is classified as a Category A bioterrorism agent and requires BSL-4 containment.

Transmission Route	Details and Clinical Significance
Bat-to-Primate	Direct contact with infected bat secretions (saliva, urine, feces) in caves or mines. Inhalation of aerosolized bat excreta is suspected but not definitively proven.
Primate-to-Human	Direct contact with blood, tissues, or cell cultures from infected nonhuman primates. Historical: 1967 outbreak via African green monkey tissue and primary cell cultures. Modern risk: zoological collections, research facilities.
Human-to-Human	Direct contact through broken skin or mucous membranes with blood, secretions, organs, or bodily fluids. Contaminated surfaces and fomites. Healthcare workers at high risk without proper PPE. NOT highly contagious via aerosol during natural outbreaks.
Experimental	Aerosol exposure in laboratory settings produces 100% lethal infections in nonhuman primates. Intramuscular, intraperitoneal, subcutaneous, intranasal, and intracerebral routes all result in fatal disease.

Etiology and Viral Classification

Virus Characteristics

Family: Filoviridae

Genus: Marburgvirus

Species: Orthomarburgvirus marburgense (includes MARV and RAVV)

Genome: Single-stranded, negative-sense RNA virus approximately 19 kilobases in length

Morphology: Pleomorphic virions appearing as filamentous particles (average 790-828 nm length, 80 nm width), U-shaped, 6-shaped, or characteristic shepherd's crook configuration. Can also appear as circular or branched forms.

NAVLE TipRemember that Marburg virus is shorter than Ebola virus (Marburg: 795-828 nm vs. Ebola: 974-1086 nm median length). Both belong to Filoviridae family and cause similar hemorrhagic fever presentations, making them clinically indistinguishable without laboratory testing.

Species	Susceptibility	Case Fatality	Clinical Notes
Rhesus Macaques	Highly susceptible	100% experimental	Gold standard NHP model for MVD research. Disease closely mimics human presentation.
Cynomolgus Macaques	Highly susceptible	100% experimental	Preferred model for vaccine and therapeutic studies. Severe disease with uniform lethality.
African Green Monkeys	Highly susceptible	100% experimental	Historical significance: source of 1967 outbreak. Not natural reservoir despite initial suspicions.
Squirrel Monkeys	Highly susceptible	100% experimental	Used in early experimental studies. Rapid disease progression.

Epidemiology and Natural History

Natural Reservoir and Geographic Distribution

Primary Reservoir: Egyptian rousette fruit bat (Rousettus aegyptiacus) of the family Pteropodidae. These bats serve as asymptomatic carriers and shed virus in saliva, urine, and feces.

Endemic Areas: Sub-Saharan Africa, particularly in countries with bat-inhabited caves and mines. Outbreaks reported in Uganda, Democratic Republic of Congo, Angola, Kenya, South Africa, Tanzania, Ghana, Equatorial Guinea, and Guinea. The most recent outbreak occurred in Rwanda in September 2024.

Historical Outbreaks and Significance

1967 Initial Outbreak: First recognized cases in laboratory workers in Marburg and Frankfurt, Germany, and Belgrade, Yugoslavia. 31 human cases with 7 deaths (23% case fatality rate). Transmission linked to African green monkeys (Cercopithecus aethiops) imported from Uganda for polio vaccine production.

Subsequent Outbreaks: Between 1967 and 2024, multiple outbreaks with varying case fatality rates (22-90%). Largest outbreak in Angola (2004-2005) with 252 cases and 90% mortality. Most cases associated with cave exploration or mining activities where bat populations reside.

Disease Stage	Clinical Signs in Nonhuman Primates
Early Phase Days 3-6	Fever: Abrupt onset with temperature spikes (peaks on days 3 and 7) Behavioral: Anorexia, lethargy, depression, decreased responsiveness Physical: Weight loss, conjunctival injection (may develop conjunctivitis) Hematologic: Profound leukopenia, early viremia detectable
Progressive Phase Days 5-7	Dermatologic: Maculopapular rash (less commonly observed in NHPs than humans) Gastrointestinal: Severe diarrhea (may be hemorrhagic), vomiting, abdominal pain Hemorrhagic: Petechiae, purpura, ecchymoses, bleeding from venipuncture sites Systemic: Continued fever, progressive weakness, dehydration
Terminal Phase Days 7-10	Hemorrhage: Uncontrolled bleeding from multiple sites (GI, mucosal surfaces, injection sites) Neurologic: Confusion, seizures, coma in some cases Multiorgan Failure: Hepatic and renal dysfunction, respiratory distress Cardiovascular: Hypotension, shock, death typically occurs days 7-10 post-infection

Transmission and Zoonotic Potential

Routes of Transmission

NAVLE TipUnlike airborne pathogens, Marburg virus does NOT spread efficiently via aerosol during natural outbreaks. However, it is classified as a Tier 1 Select Agent and Category A bioterrorism threat due to potential for weaponization via aerosol. Remember: highly infectious but not highly contagious in nature.

Organ System	Gross Pathological Findings
Liver	Hepatomegaly, pale/mottled appearance indicating fatty infiltration (steatosis), multifocal necrosis, decreased density on CT imaging
Spleen	Splenomegaly, lymphoid depletion of white pulp, fibrin deposition in red pulp, congestion
Lymph Nodes	Lymphadenopathy (especially axillary), edema, hemorrhage, lymphoid depletion
GI Tract	Hemorrhagic enteritis, mucosal ulceration, intestinal bleeding
Kidneys	Tubular necrosis, interstitial hemorrhage
Other Findings	Generalized edema, serous effusions (pleural, peritoneal), petechial and ecchymotic hemorrhages on serosal surfaces

Species Susceptibility and Pathogenesis

Nonhuman Primate Susceptibility

Diagnostic Test	Method and Timing	Clinical Significance
RT-PCR	Real-time reverse transcriptase PCR. Most sensitive early in disease. Detects viral RNA in blood, tissue.	Gold standard for early diagnosis. Can detect virus within 3 days of symptom onset. Requires BSL-4 laboratory.
Antigen-Capture ELISA	Enzyme-linked immunosorbent assay detecting viral antigens. Positive 3-7 days post-onset.	Rapid field-deployable test. Good sensitivity and specificity during acute phase. Commonly used in outbreak settings.
IgM/IgG Serology	ELISA detecting antibodies. IgM appears 5-7 days post-onset, IgG appears later (10-14 days).	Useful for retrospective diagnosis and surveillance. Not helpful in acute diagnosis. IgM indicates recent infection, IgG indicates past exposure.
Virus Isolation	Cell culture (Vero E6 cells). Requires BSL-4 containment. Time-consuming (5-7 days).	Confirmatory test but not practical for rapid diagnosis. Used for research and strain characterization.
Immunohistochemistry	Detection of viral antigens in tissue sections using specific antibodies. Performed post-mortem.	Valuable for confirming diagnosis in deceased animals. Shows tissue tropism and viral distribution.

Clinical Presentation in Nonhuman Primates

Incubation Period

Nonhuman Primates: 4-20 days (experimental studies)

Humans: 2-21 days (average 4-10 days)

Clinical Signs and Disease Progression

High-YieldKey clinical difference from humans: maculopapular rash is less commonly observed in experimentally infected NHPs. However, fever pattern (peaks on days 3 and 7), profound leukopenia, and hemorrhagic manifestations are consistent. Death typically occurs between days 7-10 in untreated animals.

Treatment Category	Interventions
Fluid Management	Aggressive IV fluid resuscitation to maintain blood pressure and perfusion Electrolyte replacement and correction of acid-base imbalances Monitor for fluid overload and pulmonary edema
Respiratory Support	Oxygen supplementation as needed Mechanical ventilation for respiratory failure Monitor oxygen saturation and blood gases
Hemodynamic Support	Vasopressor support for shock (norepinephrine, dopamine) Blood pressure monitoring (arterial line if available) Central venous access for medication administration
Hemorrhage Management	Blood transfusions (packed RBCs, fresh frozen plasma, platelets as needed) Vitamin K administration for coagulopathy Monitor coagulation parameters (PT, PTT, fibrinogen, D-dimer)
Secondary Infections	Broad-spectrum antibiotics for suspected bacterial superinfection Antifungal therapy if indicated Monitor for sepsis and treat aggressively
Nutritional Support	Enteral or parenteral nutrition if prolonged illness Maintain caloric intake to support immune function
Pain Management	Analgesics for severe myalgia and headache Avoid NSAIDs due to bleeding risk (use acetaminophen, opioids)

Pathology and Pathophysiology

Gross Pathological Findings

Histopathological Findings

Liver: Multifocal hepatocellular necrosis, microvesicular and macrovesicular steatosis, minimal inflammation, viral inclusion bodies in hepatocytes and Kupffer cells

Spleen: Diffuse lymphoid depletion, fibrin deposition, necrosis of follicular centers, viral antigen in dendriform mononuclear cells throughout red and white pulp

Lymph Nodes: Lymphoid necrosis and depletion, histiocytic infiltration, viral antigen in macrophages

Adrenal Glands: Cortical necrosis (significant finding)

Pathophysiological Mechanisms

Marburg virus disease involves:

Systemic viral replication: Virus infects dendritic cells, monocytes, macrophages, hepatocytes, and endothelial cells, leading to widespread tissue damage
Immunosuppression: Profound lymphoid depletion and impaired immune response. Virus proteins (VP35, VP40) interfere with interferon signaling
Abnormal inflammatory response: Dysregulated cytokine storm with elevated TNF-alpha, IL-6, and other pro-inflammatory mediators
Coagulation abnormalities: Disseminated intravascular coagulation (DIC), endothelial damage, and vascular permeability leading to hemorrhage and shock
Multiorgan failure: Hepatic, renal, and adrenal dysfunction culminating in hypovolemic and septic shock

NAVLE TipContrary to popular belief, hemorrhage does NOT lead to hypovolemia and is NOT the primary cause of death in MVD. Total blood loss is minimal except during parturition. Death results from multiorgan failure, shock, and severe metabolic derangements - NOT exsanguination. This is a common misconception tested on boards.

Diagnosis and Laboratory Testing

Clinical Diagnosis Challenges

MVD is clinically indistinguishable from other viral hemorrhagic fevers, particularly Ebola virus disease. Differential diagnoses in primates include malaria, typhoid fever, shigellosis, leptospirosis, rickettsial diseases, and other hemorrhagic fevers. Laboratory confirmation is mandatory.

Laboratory Diagnostic Methods

Biosafety Considerations

CRITICAL: All samples from suspected MVD cases are

Extreme biohazard risk: Requires BSL-4 containment for non-inactivated specimens
Triple packaging system: Mandatory for transport of biological specimens nationally and internationally
Personal protective equipment: Full-body suits, PAPR systems, double gloves required
Sample inactivation: Heat inactivation or chemical treatment before testing in lower containment facilities

Treatment and Management

Current Treatment Status

No FDA-approved vaccines or antiviral treatments exist for Marburg virus disease as of January 2026. Treatment is limited to intensive supportive care and management of complications.

Supportive Care Measures

Experimental Therapeutics (Research Only)

Several investigational therapies have shown promise in nonhuman primate studies:

1. Obeldesivir (ODV): Oral nucleoside analog prodrug. Recent 2025 study showed 80% protection in cynomolgus macaques when given 24 hours post-exposure for 10 days. Delays viral replication and disease onset. First oral therapeutic option showing significant promise.

2. Monoclonal Antibodies: MARV-specific monoclonal antibodies have shown efficacy in NHP models. Combination therapy with remdesivir and monoclonal antibody MR191 rescued NHPs up to 6 days post-exposure.

3. Small Molecule Antivirals: Remdesivir (partial efficacy in macaques), Favipiravir (tested but limited efficacy), Galidesivir (under investigation)

4. siRNA Therapy: Lipid nanoparticle (LNP)-encapsulated anti-MARV nucleoprotein siRNA protected 100% of rhesus macaques when initiated up to 72 hours post-infection (Angola strain).

Vaccine Development Status

Multiple vaccine candidates in development, none yet FDA-approved:

VSV-based vaccines: Recombinant vesicular stomatitis virus expressing MARV glycoprotein (VSV-MARV). Single low dose (1000 PFU) given 7-14 days pre-challenge provides 100% protection in cynomolgus macaques. Most promising candidate, modeled after successful Ebola vaccine Ervebo.

Adenovirus-based vaccines: ChAd3-MARV vector vaccine shows promise in NHP studies with single-dose protection.

DNA vaccines: Have entered Phase I clinical trials but require multiple doses and adjuvants.

Virus-like particle (VLP) vaccines: Protect NHPs from lethal aerosol exposure in experimental settings.

NAVLE TipAs of January 2026, NO vaccines or treatments are FDA-approved for MVD. If a board question asks about treatment, the correct answer is intensive supportive care. Watch for updates on obeldesivir and VSV-MARV vaccine - these are the most promising candidates and may be approved soon. The VSV-MARV vaccine is modeled after the successful Ebola vaccine Ervebo.

Prevention and Control Measures

Quarantine and Biosecurity for Imported Primates

Following the 1967 outbreak, strict quarantine protocols were implemented for imported nonhuman primates:

Minimum 31-day quarantine: All imported NHPs must undergo isolation and health monitoring
Health surveillance: Daily monitoring for fever, illness, or death during quarantine
Serological testing: Screen for filovirus antibodies before release from quarantine
Source documentation: Verify origin and health status of exporting facility
Facility requirements: Adequate biosecurity, ventilation, and waste management systems

Outbreak Control Strategies

Early case detection: Rapid identification and isolation of suspected cases
Contact tracing: Identify and monitor all potential exposures
Barrier nursing: Strict infection control measures, full PPE for healthcare workers
Safe burial practices: Minimize contact with deceased bodies; bodies remain infectious
Environmental decontamination: Thorough disinfection of contaminated areas (0.5% sodium hypochlorite effective)
Public education: Avoid contact with bats, caves, and sick/dead primates in endemic areas

Veterinary Biosafety Protocols

For veterinarians working with primates in zoological settings or research facilities:

Use appropriate PPE: Full protective equipment when handling primates with unknown health status
Minimize exposure to body fluids: Avoid needlestick injuries, mucosal splash
Report suspicious cases: Immediately notify public health authorities of suspected viral hemorrhagic fever
Post-exposure monitoring: 21-day fever watch for anyone with potential exposure

High-YieldThe risk of filovirus infection for people working with properly quarantined NHPs is minimal. After adequate 31-day quarantine with health monitoring, the risk approaches zero. However, during quarantine itself, proper biosecurity protocols are essential. Remember: humans were infected during the 1967 outbreak, but NO animal handlers were affected - only lab workers exposed to tissues and cell cultures.

Prognosis and Case Fatality

Mortality Rates

Humans: Average case fatality rate 50%, range 24-88% depending on outbreak, strain, and quality of supportive care

Nonhuman Primates: Experimentally infected NHPs: 100% mortality without treatment. Angola strain particularly virulent with rapid disease progression.

Prognostic Indicators

Poor prognostic signs: High viral load, profound leukopenia, severe coagulopathy (DIC), multi-organ dysfunction, absence of early antibody response

Better outcomes associated with: Early intensive supportive care, lower viral load, robust early immune response, absence of secondary complications

Public Health and Regulatory Considerations

Classification and Reporting

WHO Risk Group 4 Pathogen: Requires BSL-4 containment
CDC Category A Bioterrorism Agent: High-consequence pathogen with potential for weaponization
Tier 1 Select Agent: Strict regulations on possession, use, and transfer in the United States
Notifiable Disease: Immediate reporting required to public health authorities

One Health Implications

MVD exemplifies One Health principles with complex interactions between wildlife reservoirs (bats), intermediate hosts (nonhuman primates), humans, and environment (cave ecosystems). Effective prevention requires:

Ecological surveillance of bat populations in endemic regions
Monitoring of primate populations for spillover events
Community education about avoiding bat contact and cave exploration
International collaboration for outbreak response and research

Memory Tool - MARBURG Mnemonic: M = Macaque model (NHP of choice) A = African fruit bats (Rousettus reservoir) R = RNA virus (filovirus family) B = BSL-4 required (highest containment) U = Uniformly fatal in NHPs (100% experimental) R = Rash less common in NHPs than humans G = Glycoprotein vaccine (VSV-MARV most promising)

Practice NAVLE Questions

Test your knowledge with 10,000+ exam-style questions, detailed explanations, and timed exams.

Start Your Free Trial →

Marburg Virus Disease in Primates &ndash; NAVLE Study Guide